Incyte Corporation (Nasdaq:INCY) announces that 15 abstracts
from its research and development portfolio will be presented at
the upcoming 2018 American Association for Cancer Research (AACR)
annual meeting in Chicago, Illinois from April 14-18, 2018. These
abstracts include the first pre-clinical data from the Company’s
recently announced AXL/MER, TIM-3 and LAG-3 antibody programs in
patients with advanced solid tumors.
“We are excited to present a broad collection of abstracts from
our robust development portfolio at this year’s AACR Annual
Meeting,” said Reid Huber, Ph.D., Incyte’s Chief Scientific
Officer. “The acceptance of these abstracts and their results
represent the progress Incyte continues to make in the pursuit of
R&D excellence and ultimately innovation in the treatment of
cancer and other serious diseases.”
Key abstracts include:
Immuno-Therapy
Combination of a T Cell Activating Immunotherapy with Immune
Modulators Alters the Tumor Microenvironment and Promotes More
Effective Tumor Control in Preclinical Models (Abstract #1761,
Immunology – Modifiers of the Tumor Microenvironment 2)
- Monday, April 16, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 33
Identification of p-AKT as a PD marker for MER Kinase in
Human G361 Cells (Abstract #2367, Molecular and Cellular
Biology/Genetics – Kinases and Phosphatases)
- Monday, April 16, 2018, 1:00 p.m. –
5:00 p.m. CDT, Chicago, Poster Section 17
Characterization of INCB081776, a Potent and Selective Dual
AXL/MER Kinase Inhibitor (Abstract #3759, Immunology –
Immunomodulatory Agents and Interventions 1)
- Tuesday, April 17, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 32
INCAGN02390, a Novel Antagonist Antibody that Targets the
Co-Inhibitory Receptor TIM-3 (Abstract #3825, Immunology –
Therapeutic Antibodies, Including Engineered Antibodies 3)
- Tuesday, April 17, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 34
INCAGN02385 is an Antagonist Antibody Targeting the
Co-Inhibitory Receptor LAG-3 for the Treatment of Human
Malignancies (Abstract #3819, Immunology – Therapeutic
Antibodies, Including Engineered Antibodies 3)
- Tuesday, April 17, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 34
Epacadostat plus Durvalumab in Patients with Advanced Solid
Tumors: Preliminary Results of the Ongoing, Open-Label, Phase 1/2
ECHO-203 Study (Abstract #CT177, Session CTMS03 – Biomarkers in
Immuno-Oncology [minisymposium])
- Tuesday, April 17, 2018, 2:45 p.m. –
5:00 p.m. CDT, Chicago, N Hall C – McCormick Place North (Level
1)
Targeted Therapy
INCB052793, a JAK1 Selective Inhibitor, is Highly Efficacious
in PDX and Xenograft Models of Acute Myeloid Leukemia (AML)
Expressing Elevated Endogenous pSTAT3/pSTAT5 (Abstract #1867,
Experimental and Molecular Therapeutics – Experimental Agents and
Combinations for Hematologic Malignancies 2)
- Monday, April 16, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 38
The Evaluation of INCB059872, an FAD-directed Inhibitor of
LSD1, in Preclinical Models of T-ALL (Abstract #1893,
Experimental and Molecular Therapeutics – Experimental Agents and
Combinations for Hematologic Malignancies 2)
- Monday, April 16, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 38
The FAD-directed LSD1 Specific Inhibitor, INCB059872, is a
Promising Epigenetic Agent for AML Therapy by Inducing
Differentiation of Leukemic Stem/Progenitor Cells (Abstract
#1888, Experimental and Molecular Therapeutics – Experimental
Agents and Combinations for Hematologic Malignancies 2)
- Monday, April 16, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 38
INCB059872, a Novel FAD-directed LSD1 Inhibitor, is Active in
Prostate Cancer Models and Impacts Prostate Cancer Stem-like
Cells (Abstract #1379, Molecular and Cellular Biology/Genetics
– Epigenetic Therapy)
- Monday, April 16, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 16
In Vivo Assessment of the Combination of the JAK1-Selective
Inhibitor Itacitinib with First- and Second-Generation EGFR
Inhibitors in Models of Non-Small Cell Lung Cancer (Abstract
#2938, Experimental and Molecular Therapeutics – Novel Experimental
Combinations)
- Monday, April 16, 2018, 1:00 p.m. –
5:00 p.m. CDT, Chicago, Poster Section 41
The FAD-Directed LSD1 Specific Inhibitor, INCB059872,
Inhibits Cell Migration and Metastasis by Suppressing Premetastatic
Niche Formation in a Spontaneous Metastasis Mouse Model
(Abstract #3929, Experimental and Molecular Therapeutics –
Resistance and Biology)
- Tuesday, April 17, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 39
The BET Inhibitor INCB057643 Suppresses ALDH Activity by
Targeting the ALDH1A1 Super-Enhancer in High-Grade Serous Ovarian
Cancer (Abstract #3685, Clinical Research – Molecular
Classification of Tumors 1: Epigenetic Therapy, Functional and
Molecular Imaging, and Tumor Heterogeneity)
- Tuesday, April 17, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 28
Effect of JAK/STAT or PI3Kδ Plus PD-1 Inhibition on the Tumor
Microenvironment: Biomarker Results From a Phase 1b Study in
Patients with Advanced Solid Tumors (Abstract #CT176, Session
CTMS03 – Biomarkers in Immuno-oncology [minisymposium])
- Tuesday, April 17, 2018, 2:45 p.m. –
5:00 p.m. CDT, Chicago, N Hall C – McCormick Place North (Level
1)
Anti-Tumor Efficacy of INCB057643, a Novel BET Bromodomain
Inhibitor, in Castration-Resistant Prostate Cancer as Single Agent
and in Combination Therapy (Abstract #5793, Experimental and
Molecular Therapeutics – Canonical Targets 2)
- Wednesday, April 18, 2018, 8:00 a.m. –
12:00 p.m. CDT, Chicago, Poster Section 36
Full session details and data presentation listings for AACR
2018 can be found at:
http://www.abstractsonline.com/pp8/#!/4562
About Incyte
Incyte Corporation is a Wilmington, Delaware-based
biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit the Company's web site at
www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the
matters set forth in this press release, including statements
regarding the Company’s development pipeline and its presentation
plans for the upcoming AACR annual meeting, contain predictions,
estimates and other forward-looking statements. These
forward-looking statements are based on the Company’s current
expectations and subject to risks and uncertainties that may cause
actual results to differ materially, including unanticipated
developments and the risks related to the efficacy or safety of the
Company’s development pipeline, the results of further research and
development, the high degree of risk and uncertainty associated
with drug development, clinical trials and regulatory approval
processes, other market or economic factors and competitive and
technological advances; and other risks detailed from time to time
in the Company’s reports filed with the Securities and Exchange
Commission, including its Form 10-K for the year ended December 31,
2017. Incyte disclaims any intent or obligation to update these
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180315005567/en/
Incyte
ContactsMedia:Catalina Loveman+1
302-498-6171cloveman@incyte.comorInvestors:Michael Booth,
DPhil+1 302-498-5914mbooth@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Apr 2023 to Apr 2024